Accretion Nutraveda Ltd. FY26 Results: Revenue Soars, Profit Doubles

Revenue: ₹33.60 crore (FY26) vs ₹16.00 crore (FY25)
PAT: ₹5.07 crore (FY26) vs ₹2.50 crore (FY25)

Reader Takeaway: Impressive growth driven by CDMO model; watch revenue concentration and margin pressures.

What just happened

Accretion Nutraveda Ltd. announced robust financial results for the fiscal year ending March 31, 2026. The company reported a 110% year-on-year increase in revenue, reaching ₹33.60 crore, and a 102.80% rise in Profit After Tax (PAT) to ₹5.07 crore. EBITDA also saw significant growth, up 87.94% to ₹7.01 crore.

Why this matters

This performance marks a strong debut year for Accretion Nutraveda as a publicly listed entity since its IPO in February 2026. The substantial growth underscores the effectiveness of its business model as a B2B Contract Development and Manufacturing Organization (CDMO) in the nutraceutical sector, capitalizing on global outsourcing trends. The company is prioritizing reinvestment of earnings into growth initiatives.

The backstory

Accretion Nutraveda completed its Initial Public Offering (IPO) in February 2026, raising ₹24.77 crore. This funding was intended for capacity expansion and automation, aligning with its strategy to scale operations and meet growing demand.

What changes now

The company's board has opted not to recommend a dividend for FY 2025-26. Instead, it plans to retain earnings to fund growth opportunities, including further automation and expansion of its manufacturing capabilities. The company's current ratio has improved significantly to 11.98, partly due to unutilized IPO funds held in short-term deposits.

Risks to watch

Investors should be mindful of Accretion Nutraveda's revenue concentration, as a significant portion of its income comes from a few key clients. Additionally, ongoing global inflationary pressures and shipping disruptions pose potential risks to export revenues and profit margins.

Peer comparison

While specific direct peers in the nutraceutical CDMO space are not detailed in the filing, the company's growth strategy mirrors that of many contract manufacturers globally, focusing on scaling operations and leveraging outsourced manufacturing trends. However, its margins (EBITDA at 20.85%, Net Profit at 15.08%) are slightly lower than the previous year, indicating potential cost pressures or strategic investments.

Context metrics (time-bound)

• FY 2025-26 Revenue: ₹33.60 crore (up 110% YoY)
• FY 2025-26 PAT: ₹5.07 crore (up 102.80% YoY)
• FY 2025-26 EBITDA: ₹7.01 crore (up 87.94% YoY)
• Current Ratio: 11.98 (up from 2.87)
• IPO Funds Raised: ₹24.77 crore (February 2026)

What to track next

Investors will be keen to see how Accretion Nutraveda deploys its IPO funds for capacity expansion and automation. Monitoring client diversification efforts to reduce revenue concentration and the sustainability of margins amidst market risks will be crucial.